PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901543
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901543
The Imaging Biomarkers Market size was valued at US$ 13,678.45 Million in 2024, expanding at a CAGR of 12.5% from 2025 to 2032.
The imaging biomarkers market is expanding rapidly, driven by advancements in quantitative imaging, AI-based analysis, and precision medicine. Imaging biomarkers enable the noninvasive assessment of physiological, molecular, and structural processes, improving disease diagnosis, prognosis, and therapy monitoring. Modalities such as MRI, CT, PET, and ultrasound are increasingly used to extract measurable imaging metrics that act as surrogate endpoints in clinical trials and personalized treatment plans. Rising demand for early disease detection, growth in clinical research, and integration of radiomics and machine learning technologies further propel market growth. The market faces restraints such as high costs of imaging systems and biomarker validation, lack of standardized imaging protocols.
Imaging Biomarkers Market- Market Dynamics
Technological advancements
The imaging biomarkers sector has grown in recent years as a result of significant improvements in molecular diagnostics. Cizzle Biotech launched the CIZ1B biomarker assay in March 2025, a non-invasive blood test for detecting lung cancer at an early stage. This assay can be used to supplement imaging-based diagnostic procedures like as CT and PET scans by detecting high-risk individuals, allowing them to be treated sooner, and improving diagnostic processes. The collaboration with iGenomeDX will give scalable access in the United States, enhancing accessibility and enabling the use of molecular and imaging biomarkers.
The Global Imaging Biomarkers Market is segmented on the basis of Type, Technology, Application, End User, and Region.
The market is divided into three categories based on Type: Reagents & Kits, Instruments & Systems, and Software & Services. Reagents & kits dominate due to high testing frequency, while instruments & systems support automation and accuracy, and software & services enable efficient data analysis, workflow management, and integration.
The market is divided into six categories based on Technology: PCR, Next-Generation Sequencing (NGS), In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, and Other Technologies. NGS enables genomic profiling; In situ Hybridization offers spatial analysis; microarrays and mass spectrometry enhance multiplexing and precision, while other technologies support specialised and emerging diagnostic applications.
Imaging Biomarkers Market- Geographical Insights
The Imaging Biomarkers market exhibits significant geographical insights in 2025, with North America leading as the largest market. North America captures a significant market share, driven by robust research and development activities, advanced healthcare infrastructure, high prevalence of chronic and infectious diseases, and strong demand for personalised medicine. The region benefits from substantial investments in healthcare and biotechnology, contributing to widespread adoption of molecular diagnostic technologies in hospitals, laboratories, and research centres. Asia Pacific emerges as the fastest-growing region, which is fueled by increasing healthcare spending, expanding government initiatives to enhance healthcare infrastructure, rising prevalence of infectious and chronic diseases, and technological advancements. Europe holds a significant market size with growing investments in research and an ageing population, contributing to increasing demand for Imaging Biomarkers. Other regions, such as Latin America and the Middle East & Africa, are also witnessing market growth due to improving healthcare infrastructure and rising disease burden.
Imaging Biomarkers Market- Country Insights
The United States Imaging Biomarkers market was reflecting a significant CAGR. This growth is primarily driven by advancements in diagnostic technologies, increasing demand for personalised medicine, and a rising incidence of infectious diseases and cancer in the country. The U.S. healthcare system's focus on early disease detection and precision medicine contributes to the widespread adoption of Imaging Biomarkers across hospitals, diagnostic centres, and research institutions. Key technologies such as liquid biopsy and next-generation sequencing (NGS) are increasingly utilised to enhance diagnostic accuracy and targeted therapy selection, especially in oncology. Additionally, the rising prevalence of infectious diseases like COVID-19, influenza, and HIV fuels demand for rapid and accurate molecular testing.
The Imaging Biomarkers market's competitive landscape in 2025 is led by several major global players that drive innovation and market growth through robust Type portfolios, technological advancements, and strategic expansions. For instance, in August 2024, Sysmex Corporation expanded its strategic alliance with QIAGEN to deepen collaboration in genetic testing, covering research and development, Typeion, clinical trials, and global sales and marketing. This alliance builds upon their initial 2021 partnership focused on cancer companion diagnostics using ultra-sensitive liquid biopsy NGS technology. Additionally, the market players are actively engaged in Type launches, regulatory approvals, acquisitions, and partnerships to enhance their market presence. Moreover, the collaborative efforts of market players, coupled with continuous R&D, enable the Imaging Biomarkers market to grow robustly, addressing diverse clinical needs globally.
In March 2025, Danaher Corporation, through subsidiaries like Beckman Coulter, is investing in automated and high-throughput molecular diagnostic solutions to support diverse clinical needs.
In February 2023, Becton Dickinson (BD) received FDA Emergency Use Authorisation (EUA) for a molecular diagnostic test capable of detecting and differentiating COVID-19, influenza A/B, and respiratory syncytial virus (RSV). This test, designed for use on the BD MAX Molecular Diagnostic System, uses a single nasal or nasopharyngeal swab sample.